Oral contraception and the recognised gynaecological indications for such oestrogen-progestogen combinations. The decision to prescribe Microgynon 30 should take into consideration the individual woman's current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Microgynon 30 compares with other combined hormonal contraceptives (CHCs) (see sections 4.3 and 4.4).
Oral contraception and the recognised gynaecological indications for such oestrogen-progestogen combinations. The decision to prescribe Microgynon 30 ED should take into consideration the individual woman's current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Microgynon 30 ED compares with other combined hormonal contraceptives (CHCs) (see sections 4.3 and 4.4).